Sientra, Inc. Provides Revenue Guidance for the First Quarter and Earnings Guidance for the Full Year of 2023
March 30, 2023 at 04:21 pm EDT
Share
Sientra, Inc. provided revenue guidance for the first quarter and earnings guidance for the full year of 2023. For full year 2023, the company expects to achieve total net sales of $104 million to $109 million, representing growth of 15% to 20% compared to net sales of $90.5 million in 2022.
The company revenue estimates for first quarter 2023 to be between $22 million and $23 million, or growth of 3% to 8% versus prior year.
Project Sage Oldco Inc., formerly Sientra, Inc., is a medical aesthetics company. The Company is engaged in transformative treatments and technologies focused on advancing plastic surgery. The Company provides medical aesthetics products to certified plastic surgeons and patients. It has developed a portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants, breast tissue expanders, and fat transfer system for reconstruction procedures predominantly to hospitals and surgery centers, and its BIOCORNEUM scar management products to plastic surgeons, dermatologists and other specialties. The Company's brands also include Sientra, Sientra Platinum20, Sientra Full Circle, Sientra Smooth, Sientra Teardrop, AlloX, AlloX2, Anatomical Controlled, BIOCORNEUM, Curve, Dermaspan, Luxe, Softspan, Silishield, AuraClens and Viality.
PROJECT SAGE OLDCO, INC. 
